Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced on Jan 27, 2026 that the Mexican Institute of Industrial Property (IMPI) issued a Notice of Allowance for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection in Mexico and expands the company’s international intellectual property estate, complementing patents in the United States and other jurisdictions. Anixa said the allowance supports future regulatory, development, and potential partnering efforts while clinical development continues in the U.S.

The release highlights Mexico’s later-stage breast cancer diagnoses and higher triple-negative breast cancer incidence as a strategic rationale for the patent.

Positive

• IMPI issued a Notice of Allowance for Anixa breast cancer vaccine
• Patent provides composition-of-matter protection in Mexico
• Patent is exclusively licensed from Cleveland Clinic
• Expands international patent estate complementing U.S. patents

Negative

• Clinical development remains ongoing in the U.S.; no commercial revenue yet
• Patent allowance covers Mexico only, not global commercialization
• Release contains no financial or timing guidance for commercialization

News Market Reaction – ANIX

-0.32%

2 alerts

-0.32% News Effect

-3.9% Trough Tracked

-$331K Valuation Impact

$103M Market Cap

0.8x Rel. Volume

On the day this news was published, ANIX declined 0.32%, reflecting a mild negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $331K from the company's valuation, bringing the market cap to $103M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.88 Vol: Volume 253,388 is modestl...

normal vol

$2.88 Last Close

Volume Volume 253,388 is modestly above the 20-day average of 226,225, suggesting only slightly elevated trading interest into this patent news. normal

Technical Shares at $3.09 are trading below the 200-day MA of $3.39 and sit 43.37% under the 52-week high.

Peers on Argus

ANIX fell 5.21% while peers were mixed: SRZN and STTK were up, ADAG was modestly...

ANIX fell 5.21% while peers were mixed: SRZN and STTK were up, ADAG was modestly positive, TCRX was flat, and PYXS declined. This pattern points to stock-specific pressure rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 15	IND transfer update	Positive	-8.9%	Completion of IND transfer and plan to advance breast cancer vaccine to Phase 2.
Dec 11	Phase 1 data	Positive	-6.4%	Final Phase 1 breast cancer vaccine data meeting endpoints with 74% immune response.
Dec 10	Investor fireside chat	Neutral	+1.4%	Announcement of CEO participation in a fireside chat discussing Phase 1 results.
Dec 09	Data presentation notice	Positive	-3.1%	Notice that final Phase 1 breast cancer vaccine results would be presented at SABCS.
Nov 17	CAR-T INN approval	Positive	+2.2%	WHO approval of an International Nonproprietary Name for the FSHR-targeted CAR-T therapy.

Pattern Detected

Recent history shows several positive clinical and development updates followed by negative price reactions, indicating a tendency for sell-the-news behavior around Anixa milestones.

Recent Company History

Over the past few months, Anixa has advanced its oncology pipeline with multiple catalysts. In December 2025, positive Phase 1 data for its α-lactalbumin breast cancer vaccine and the IND transfer to Anixa still saw shares decline after those announcements. Earlier, the WHO’s approval of the INN for its CAR-T therapy on Nov. 17, 2025 coincided with a modest gain. Today’s Mexican patent allowance for the breast cancer vaccine extends that same program’s global footprint, fitting into a pattern of steady IP and clinical progress versus mixed market reactions.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-10

Anixa filed an S-3 shelf registration on 2025-09-10, outlining a range of potential securities, but the filing is not yet effective and there have been 0 recorded usage events to date.

Market Pulse Summary

This announcement extends Anixa’s breast cancer vaccine intellectual property into Mexico via a Noti...

Analysis

This announcement extends Anixa’s breast cancer vaccine intellectual property into Mexico via a Notice of Allowance, complementing patents in the U.S. and other regions. It strengthens protection around the α-lactalbumin “retired protein” strategy and supports future ex-U.S. development and partnering discussions. Recent history includes completion of a Phase 1 trial with encouraging immune data and an active oncology pipeline. Investors may monitor future clinical readouts, regional regulatory steps, and how the company utilizes its capital-raising tools.

Key Terms

notice of allowance, composition of matter, triple-negative breast cancer, cancer immunotherapy, +2 more

6 terms

notice of allowance regulatory

"the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

composition of matter regulatory

"will provide composition of matter protection for the Company's novel approach"

Composition of matter describes the specific chemical makeup and structure of a substance — essentially the “recipe” of which atoms or molecules are present and how they are arranged. For investors, it matters because that precise recipe is what patents, regulatory approvals, and product claims protect; control over a unique composition can create market exclusivity, influence manufacturing costs, and drive a company’s valuation or licensing potential.

triple-negative breast cancer medical

"higher triple-negative breast cancer incidence rates"

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

cancer immunotherapy medical

"reinforcing its leadership in the field of cancer immunotherapy."

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

α-lactalbumin medical

"based on immunizing against human α-lactalbumin, a protein associated with lactation"

α-lactalbumin is a naturally occurring protein found in mammalian milk that supplies essential building blocks and supports nutrient absorption; think of it as a concentrated, high-quality protein ingredient used to boost the nutritional value of infant formula, medical nutrition and some supplements. Investors care because its use, purity, and supply affect product claims, regulatory approvals, patent positions and consumer demand in nutrition and health markets—factors that influence revenue and margins.

retired protein medical

"This "retired" protein strategy, developed at Cleveland Clinic and licensed"

A retired protein is a biological molecule that a company has deliberately stopped using, developing, or selling — for example as a drug ingredient, diagnostic marker, vaccine component, or research target — because it failed tests, raised safety or regulatory concerns, or was replaced by a better option. For investors, a protein’s retirement can signal changes in a company’s pipeline value, future revenue prospects, regulatory risk and potential liabilities, similar to a manufacturer discontinuing a product line and shifting resources to newer models.

AI-generated analysis. Not financial advice.

Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine

Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates

SAN JOSE, Calif., Jan. 27, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in Mexico.

With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Mexican patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.

"This newly allowed patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."

Breast cancer is typically diagnosed at later stages in Mexico than in the U.S., causing challenges for patients and their physicians. Further, Mexican women have a higher incidence rate of triple-negative breast cancer—the most lethal form of breast cancer.

Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-mexican-institute-of-industrial-property-impi-for-patent-covering-breast-cancer-vaccine-technology-302670617.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa (ANIX) announce on January 27, 2026 regarding Mexico?

Anixa received a Notice of Allowance from IMPI for a patent on its breast cancer vaccine technology.

Does the Mexican patent for Anixa (ANIX) cover composition of matter?

Yes, the allowed patent provides composition-of-matter protection in Mexico for the vaccine technology.

Is the Mexican patent for Anixa (ANIX) independently owned or licensed?

The patent is exclusively licensed from Cleveland Clinic to Anixa.

How does the IMPI allowance affect Anixa (ANIX) commercialization plans?

The allowance strengthens Anixa’s international IP position for future regulatory and partnering efforts but does not announce commercialization timing.

Why is a Mexican patent relevant for Anixa (ANIX)?

Mexico has later-stage breast cancer diagnoses and higher triple-negative incidence, making IP protection there strategically important.